Last reviewed · How we verify

NCT06587347: TREND-2

Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke

Not yet recruiting Phase 2, PHASE3 Last updated 29 October 2024
What this trial tests

Phase 2, PHASE3 trial testing Tirofiban Hydrochloride in Acute Stroke in 302 participants. Not yet recruiting.

Timeline
20 November 2024
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorCapital Medical University
PhasePhase 2, PHASE3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment302
Start date20 November 2024
Primary completion30 June 2026
Estimated completion30 June 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Capital Medical University

Who can join

18 and older, any sex, with Acute Stroke or Ischemic Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, multicenter, randomized, controlled, open-label, blinded endpoint trial to evaluate the safety and efficacy of intravenous administration of tirofiban for preventing early neurological deterioration after intravenous thrombolysis in patients with acute ischemic stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tirofiban Hydrochloride

Trials testing the same drug.

Other recruiting trials for Acute Stroke

Currently open trials in the same condition.

Other Capital Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06587347.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing